Uncertainty around pharma tariffs on and pricing policies under the Trump has much of the sector guessing what will happen ...

Two research articles published in Nature Genetics shed new light on the cellular complexity of glioblastoma, the most ...

In this article, we are going to take a look at where Regeneron Pharmaceuticals ... of tariffs is expected to shift lower as and when the deals are made, supply chains adapt, and there is some ...

On Tuesday, Regeneron Pharmaceuticals Inc (NASDAQ:REGN) reported first-quarter adjusted earnings per share of $8.22, down 14% year-over-year, missing the consensus of $8.82. The company reported ...

Regeneron Q1 EPS fell 14% to $8.22, missing estimates; revenue dropped 4% to $3.03 billion, also below consensus. Eylea sales fell 26% to $1.04 billion amid pricing pressure and market share loss ...

Shares of biotech company Regeneron (NASDAQ:REGN) fell 9.6% in the morning session after the company reported weak first-quarter 2025 results. Its revenue missed significantly, and its EPS fell short ...

"Regeneron has one of the most exciting pipelines in the industry, with unmatched diversity, scientific distinction, and potential to help millions of patients," said Leonard S. Schleifer ...

Regeneron Pharmaceuticals' first-quarter net income rose but revenue fell due to inventory issues and generic competition for its best-selling biopharmaceuticals, and the company trimmed its ...

By leveraging AI to help predict client purchasing patterns with up to 97% accuracy ... 20% increase in employee productivity and a 15% boost in customer satisfaction. Regeneron: A leading ...

TARRYTOWN, N.Y. (AP) — TARRYTOWN, N.Y. (AP) — Regeneron Pharmaceuticals Inc. (REGN) on Tuesday reported first-quarter profit of $808.7 million. The Tarrytown, New York-based company said it ...